An interventional study of Clinical program in Venous Thromboembolism and Neoplasms, sponsored by University of Vermont. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.
Sponsored by University of Vermont · Not applicable, Interventional, and Other
assess effectiveness of a , compared with usual care, to assess
The goal of this study is to learn if a modified clinical program can improve adherence to guideline recommendations for prevention of venous thromboembolism in ambulatory patients with cancer. The main question[s] it aims to answer are:
Does the modified program improve number of ambulatory oncology patients starting systemic treatment getting VTE risk-assessment? Does the modified program improve the number of patients receiving appropriate preventative anticoagulation? Researchers will compare to usual care (no clinical program).
Participant clinicians will be asked to
694 studies on the registry are indexed under Venous Thromboembolism; 151 are open to participants now.
This study's planned enrollment of 25 is below the median of 259 across 382 interventional studies indexed under Venous Thromboembolism.
Browse Venous Thromboembolism studies →University of Vermont is the lead sponsor of 215 studies on the registry; 28 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Clinical program
Revised Vermont Model clinical program, including standardized education and training for oncology care team, clinical decision support and revised workflow for VTE risk assessment and thromboprophylaxis.
Documented VTE risk assessment
Proportion of new patients who have documented VTE risk assessment
Time frame: 30 days after new patient appointment
Appropriate thromboprophylaxis
Proportion of identified high-risk patients with prescription for thromboprophylaxis and low-risk patients without thromboprophylaxis
Time frame: 30 days after new patient appointment
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Vermont